Chart of Day: Revisiting Viking Therapeutics (VKTX) – 2/27

The last time we mentioned Viking Therapeutics (VKTX), we said:

While the obesity drug stock has already exploded, it could see higher highs. At the moment, Viking Therapeutics and its potential treatment for obesity – VK2735, has already shown a mean weight loss of up to 18 pounds from baseline. The company also initiated Phase 1 clinical study to evaluate a novel oral formulation of VK2735.”


That was on February 20, as VKTX traded at around $35.  Today, it’s up to $37.42 and we still strongly believe it could see higher highs.

Should VKTX see even better results, it could be exposed to a significant opportunity.

Remember, the obesity story is bursting at the seams.

According to the World Health Organization, obesity has tripled since 1975.  More than 1.9 billion adults were overweight as of 2016, with more than 650 million considered obese. Plus, more than 340 million children were considered overweight in 2016 as well.

However, if millions of people can take a pill or get a shot to help lose weight, it could create an unbelievable opportunity for VKTX – just as it has for other related companies.

deal of the month

best growth stocks


Bundle package – lifetime subscriptions for all products


Recent posts


Connect with Us

Get FREE Daily Stock Tips

Join and receive market insider stock picks, trade alerts and unique investing insights
This field is for validation purposes and should be left unchanged.
By clicking the "Subscribe" button you are accepting our Terms of Use and Privacy Policy.

Join Waitlist

We’re sorry, but due to the popularity of our services, we have reached our max number of subscribers and are not currently accepting more. If spots become available, we will be sure to contact you. Please join the waitlist below.
Thank You!

"*" indicates required fields

This field is for validation purposes and should be left unchanged.